Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Biobanking Study in Cancer Patients Aiming at Better Understand the Link Between the Molecular Alterations of the Tumor Itself, Its Microenvironment and Immune Response (SCANDARE)

NCT03017573 is registered in ClinicalTrials.gov with Institut Curie as lead sponsor.

NCT NCT03017573
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03017573 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Biobanking Study in Cancer Patients Aiming at Better Understand the Link Between the Molecular Alterations of the Tumor Itself, Its Microenvironment and Immune Response (SCANDARE)
Lead sponsor
Institut Curie
Phase
Not applicable
Overall status
Recruiting
Start date
January 6, 2017
Completion date
January 6, 2032
Enrollment
1,050 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

cervical cancer, head and neck cancer, ovarian cancer, sarcoma, triple-negative breast cancer, vulva cancer